News
AYTU
1.230
+2.08%
0.025
Weekly Report: what happened at AYTU last week (0310-0314)?
Weekly Report · 15h ago
Weekly Report: what happened at AYTU last week (0303-0307)?
Weekly Report · 03/10 12:34
COO’s Bold Move: Major Stock Purchase in Aytu BioScience!
TipRanks · 03/04 02:06
Weekly Report: what happened at AYTU last week (0224-0228)?
Weekly Report · 03/03 12:33
Based on the provided financial report articles, the title of the article is: "AYTU 2024 Q2 10-Q Filing: Form 10-Q for the quarterly period ended June 30, 2024" This title indicates that the article is a quarterly report (Form 10-Q) filed by Aytu BioScience, Inc. (AYTU) with the Securities and Exchange Commission (SEC) for the period ended June 30, 2024.
Press release · 03/01 09:34
Weekly Report: what happened at AYTU last week (0217-0221)?
Weekly Report · 02/24 12:33
Weekly Report: what happened at AYTU last week (0210-0214)?
Weekly Report · 02/17 12:29
Aytu BioScience: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
TipRanks · 02/14 12:46
Aytu BioScience Earnings Call: Growth Amid Challenges
TipRanks · 02/14 00:27
Aytu BioPharma Reports Strong Q2 Earnings Growth
TipRanks · 02/13 04:06
Based on the provided financial report articles, the title of the article is: "AYTU 2024 Q2 10-Q Filing: Form 10-Q for the quarterly period ended June 30, 2024" This title indicates that the article is a quarterly report (Form 10-Q) filed by Aytu BioScience, Inc. (AYTU) with the Securities and Exchange Commission (SEC) for the quarter ended June 30, 2024.
Press release · 02/13 00:03
Aytu BioPharma anticipates positive cash flow with ADHD growth and $2M annual cost savings
Seeking Alpha · 02/12 23:35
Aytu BioPharma GAAP EPS of -$0.26 beats by $0.02, revenue of $16.22M beats by $0.67M
Seeking Alpha · 02/12 22:00
Aytu Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 02/12 21:50
Aytu BioPharma Q2 EPS $(0.28), Inline, Sales $16.22M Beat $15.55M Estimate
Benzinga · 02/12 21:14
AYTU BIOPHARMA Q2 EPS USD 0.13
Reuters · 02/12 21:04
Here are the major earnings after the close today
Seeking Alpha · 02/12 15:00
Earnings Scheduled For February 12, 2025
Benzinga · 02/12 08:32
Weekly Report: what happened at AYTU last week (0203-0207)?
Weekly Report · 02/10 12:19
Weekly Report: what happened at AYTU last week (0127-0131)?
Weekly Report · 02/03 12:27
More
Webull provides a variety of real-time AYTU stock news. You can receive the latest news about Aytu Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About AYTU
More
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.